GE Healthcare Technologies (GEHC) said Thursday it took on the lead industrial role in the COMPASS consortium, a new public-private partnership aimed at advancing cardio-oncology care across Europe.
The five-year project, with a total budget of 50.5 million euros ($58.3 million), focuses on advancing the early detection of cardiovascular risks in cancer patients, the company said.
The project is co-funded under the Horizon Europe framework as part of the Innovative Health Initiative, which is a public-private partnership between the EU and the European life science industries, according to a statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments